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Summary
Background Heart failure is a global public health problem, affecting a large number of individuals from low-income 
and middle-income countries. REPORT-HF is, to our knowledge, the first prospective global registry collecting 
information on patient characteristics, management, and prognosis of acute heart failure using a single protocol. The 
aim of this study was to investigate differences in 1-year post-discharge mortality according to region, country income, 
and income inequality.
Methods Patients were enrolled during hospitalisation for acute heart failure from 358 centres in 44 countries on 
six continents. We stratified countries according to a modified WHO regional classification (Latin America, North 
America, western Europe, eastern Europe, eastern Mediterranean and Africa, southeast Asia, and western Pacific), 
country income (low, middle, high) and income inequality (according to tertiles of Gini index). Risk factors were 
identified on the basis of expert opinion and knowledge of the literature.
Findings Of 18 102 patients discharged, 3461 (20%) died within 1 year. Important predictors of 1-year mortality were 
old age, anaemia, chronic kidney disease, presence of valvular heart disease, left ventricular ejection fraction 
phenotype (heart failure with reduced ejection fraction [HFrEF] vs preserved ejection fraction [HFpEF]), and being on 
guideline-directed medical treatment (GDMT) at discharge (p<0·0001 for all). Patients from eastern Europe had the 
lowest 1-year mortality (16%) and patients from eastern Mediterranean and Africa (22%) and Latin America (22%) the 
highest. Patients from lower-income countries (ie, ≤US$3955 per capita; hazard ratio 1·58, 95% CI 1·41–1·78), or 
with greater income inequality (ie, from the highest Gini tertile; 1·25, 1·13–1·38) had a higher 1-year mortality 
compared with patients from regions with higher income (ie, >$12 235 per capita) or lower income inequality (ie, 
from the lowest Gini tertile). Compared with patients with HFrEF, patients with HFpEF had a lower 1-year mortality 
with little variation by income level (pinteraction for HFrEF vs HFpEF <0·0001).
Interpretation Acute heart failure is associated with a high post-discharge mortality, particularly in patients with 
HFrEF from low-income regions with high income inequality. Regional differences exist in the proportion of eligible 
patients discharged on GDMT, which was strongly associated with mortality and might reflect lack of access to post-
discharge care and prescribing of GDMT.
Funding Novartis Pharma.
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Introduction
Worsening heart failure is a common cause of hospital 
admission in people aged older than 65 years and is 
associated with a high subsequent mortality; it is, therefore, 
a global health priority.1 In the past decade, attempts to 
improve the outcomes of patients with acute heart failure 
have been largely ineffective. Despite indivi duals from low-
income and middle-income countries being at risk of 
developing heart failure at a younger age (ie, <65 years), and 
the majority of admissions to hospital for acute heart failure 
occurring in these regions, data on patient characteristics 
and post-discharge outcomes on acute heart failure from 
low-income and middle-income countries are scarce.2–4
Marked differences in prognosis among world regions 
have been reported from international clinical trials of 
interventions for both acute and chronic heart failure, 
but patients in trials are highly selected, managed 
differently, and are unlikely to be representative of those 
managed as part of usual clinical care.5–10 The scarcity 
of data available from registries, mostly on chronic 
heart failure, suggest marked differences in patient 
charac teristics and worse outcomes in low-income 
and middle-income countries.4,11 Unfortunately, little 
compre hensive data have been collected simultaneously 
to quantify and compare international differences 
and factors associated with post-discharge outcomes 
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from a large, representative population with acute 
heart failure.
The international registry to assess medical practice 
with longitudinal observation for treatment of heart 
failure (REPORT-HF) was specifically designed to assess 
international variations in clinical practice patterns and 
outcomes for patients with acute heart failure.12 The aim 
of this analysis was to assess differences in 1-year post-
discharge mortality according to region, country income, 
and income inequality.
Methods
Study design and setting
The design and methods of the REPORT-HF study have 
previously been described.12 In brief, REPORT-HF is an 
observational, prospective, global cohort study with 
patients prospectively enrolled across 358 sites from 
44 countries on six continents. At many sites, the volume 
of patients in relationship to the research resource 
available was sufficiently high such that sites were 
enrolled on predetermined days of the week or weeks of 
the month. The original sample size of the study was 
proposed to be 20 000 patients to estimate comparisons 
of interest and taking into account potential loss to 
follow-up with an assumed 30% attrition. Comparisons 
of interest required at least 300 patients per group to 
detect a margin of difference of up to 10%. As part of 
the prespecified analysis, the target sample size was 
re-evaluated during the study enrolment period, resulting 
in a revised estimated attrition rate of approximately 25% 
rather than the estimated 30% loss of information. The 
sample size was therefore adjusted to 18 700 for the total 
cohort. The first patient was enrolled on July 23, 2014, and 
last patient March 24, 2017.
This study was done in accordance with the Declaration 
of Helsinki, and the protocol received approval from the 
institutional review board, or ethics committee, or both, 
at each participating centre.
Participants
Participants were adults hospitalised with a primary 
diagnosis of acute heart failure according to the treating 
physician.12 Consecutive eligible patients (ie, patients 
hospitalised with a primary diagnosis of new-onset, 
first diagnosis heart failure or decompensation of 
chronic heart failure as assessed by the clinician-
investigator) were asked to give consent. Written 
informed consent was obtained from all patients or a 
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Research in context 
Evidence before this study
We searched MEDLINE and Embase from Jan 1, 1985, until 
May 1, 2019, for relevant articles published in English on 
differences in post-discharge outcomes of patients hospitalised  
for acute heart failure according to region, country income 
classification, or country income inequality, using the terms “heart 
failure” OR “acute heart failure” AND “outcome” OR “mortality” 
AND “regional” OR “international” OR “income” OR “Income 
inequality”. Most reports on regional differences in acute heart 
failure-related mortality were from clinical trials that had many 
inclusion and exclusion criteria and might not have been 
epidemiologically representative of the global problem. Registry 
data usually focused on specific regions such as Europe, or 
countries such as the USA, Japan, and South Korea, which makes 
inter-regional comparisons difficult. Furthermore, few registries 
included patients from lower-income countries. Data on the 
effects of country income classification are limited to one post-hoc 
analysis of a trial of acute heart failure that included few lower-
income countries. No study has investigated the association 
between country-level income inequality and post-discharge 
outcomes in acute heart failure. We found that reports varied 
considerably on regional differences in post-discharge outcomes 
for acute heart failure, probably because of differences in trial 
inclusion criteria. We found no study with global representation of 
an unselected acute heart failure population.
Added value of this study
REPORT-HF is, to our knowledge, the first large, prospective 
registry of acute heart failure specifically designed to study 
worldwide variations in clinical practice patterns and 
outcomes among a large number of countries at different 
economic levels. Our study provides new information on 
global differences in post-discharge mortality for acute heart 
failure, setting a standard for future clinical and public health 
interventions. Post-discharge mortality remains high globally, 
especially for those with heart failure with reduced ejection 
fraction (HFrEF) from low-income regions with high income 
inequality. Regional differences were observed in the 
proportion of eligible patients with HFrEF who were 
discharged on guideline-directed medical treatment (GDMT), 
which was strongly associated with mortality. Variations in 
access and implementation of GDMT might explain regional 
variation in mortality for HFrEF. Scarcity of effective 
treatments for heart failure with preserved ejection fraction 
(HFpEF) might explain why there is much less international 
variability in outcome.
Implications of all the available evidence
Differences in outcome according to national income and 
income inequality might reflect that component of risk that is 
modifiable with optimal contemporary care. After an episode of 
acute heart failure, patients with HFrEF from countries with 
lower income or greater income inequality have a substantially 
higher 1-year mortality, but patients with HFpEF do not. Low 
uptake of GDMT for HFrEF observed in lower-income countries 
might explain higher national mortality rates and this 
inequality might be eliminated by improved access to care 
and medications.
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legal representative, if permitted. Those unable or 
unwilling to provide informed consent could not be 
included. The only other exclusion criterion was 
participation in a clinical trial with any investigational 
treatment.
Procedures
During the index hospitalisation, data were collected on 
patient demographics, medical history, comorbidities, 
and admission and discharge medications, as well as 
vital signs, physical exam, laboratory values, acute 
therapies and procedures, and hospital course, including 
length of stay and mortality. Data were captured in 
a central electronic database using the same case report 
form at all sites and reviewed by central data management 
and clinical groups that raised queries, which were then 
resolved by local study monitors.
Heart failure with reduced ejection fraction (HFrEF) 
was defined as a left ventricular ejection fraction (LVEF) 
of less than 40%, heart failure with mid-range ejection 
fraction (HFmrEF) was defined as an LVEF 40–49%, and 
heart failure with preserved ejection fraction (HFpEF) 
was defined as a LVEF of at least 50%. Coronary artery 
disease was defined as having a history of coronary artery 
bypass grafting, percutaneous coronary intervention, 
acute coronary syndrome, or myocardial infarction. 
History of valve disease was defined as a positive history 
of valve disease or valvular surgery at discharge. At the 
6-month follow-up visit, data on medication use was 
collected. Medication data were acquired through follow-
up with the patient or primary care provider, or both, 
where medicine name, doses, and units were captured. 
There were programmed database edits checks and 
manual data review with queries if no medications were 
recorded and manual review with queries if doses or 
units were off for any of the cardiovascular medications. 
Additional data quality checks were done using the 
records provided at the analysis stage.
Total 
(N=18 102)
Central and 
South America 
(n=2525)
Eastern 
Europe 
(n=2761)
Eastern 
Mediterranean 
region and 
Africa (n=2172)
North America 
(n=1565)
Southeast 
Asia (n=2292)
Western 
Europe 
(n=3489)
Western 
Pacific 
(n=3298)
p value*
Demographics
Sex†
Female 7003 (39%) 1016 (40%) 1148 (42%) 818 (38%) 644 (41%) 834 (36%) 1243 (36%) 1300 (39%) NA
Male 11 099 (61%) 1509 (60%) 1613 (58%) 1354 (62%) 921 (59%) 1458 (64%) 2246 (64%) 1998 (61%) <0·0001
Age, years† 67 (57–77) 67 (57–77) 68 (60–77) 64 (55–73) 63 (54–73) 61 (53–70) 75 (65–81) 67 (56–77) <0·0001
BMI, kg/m² 26 (23–31) 25 (22–30) 27 (24–31) 27 (24–31) 29 (24–36) 23 (20–26) 27 (24–32) 24 (21–27) <0·0001
Missing 9396 (52%) 1668 (66%) 1531 (55%) 1414 (65%) 133 (8%) 1347 (59%) 1694 (49%) 1609 (49%) NA
Obesity ·· ·· ·· ·· ·· ·· ·· ·· <0·0001
BMI ≤30 kg/m² 2850 (16%) 243 (10%) 524 (19%) 269 (12%) 772 (49%) 97 (4%) 690 (20%) 255 (8%) NA
Missing 9396 (52%) 1668 (66%) 1531 (55%) 1414 (65%) 133 (8%) 1347 (59%) 1694 (49%) 1609 (49%) NA
Race† ·· ·· ·· ·· ·· ·· ·· ·· <0·0001
White 9409 (52%) 1019 (40%) 2738 (99%) 1382 (64%) 775 (50%) 0 3402 (98%) 93 (3%) NA
Black 852 (5%) 90 (4%) 0 44 (2%) 701 (45%) 1 (<1%) 14 (<1%) 2 (<1%) NA
Asian 5642 (31%) 2 (<1%) 9 (<1%) 100 (5%) 27 (2%) 2289 (100%) 23 (1%) 3192 (97%) NA
Native American 364 (2%) 356 (14%) 0 0 6 (<1%) 0 2 (<1%) 0 NA
Pacific Islander 7 (<1%) 3 (<1%) 0 0 2 (<1%) 0 2 (<1%) 0 NA
Other 1828 (10%) 1055 (42%) 14 (1%) 646 (30%) 54 (4%) 2 (<1%) 46 (1%) 11 (<1%) NA
Heart failure diagnosis ·· ·· ·· ·· ·· ·· ·· ·· <0·0001
DCHF† 10 353 (57%) 1504 (60%) 1842 (67%) 1347 (62%) 1249 (80%) 487 (21%) 2177 (62%) 1747 (53%) NA
NYHA class ·· ·· ·· ·· ·· ·· ·· ·· <0·0001
I 837 (8%) 153 (9%) 65 (4%) 158 (9%) 15 (3%) 109 (9%) 180 (10%) 157 (7%) NA
II 3226 (29%) 549 (33%) 479 (26%) 543 (31%) 135 (28%) 314 (25%) 582 (31%) 624 (28%) NA
III 4959 (45%) 736 (44%) 962 (53%) 693 (39%) 263 (55%) 401 (32%) 895 (48%) 1009 (46%) NA
IV 2050 (19%) 240 (14%) 326 (18%) 372 (21%) 68 (14%) 417 (34%) 216 (12%) 411 (19%) NA
Missing 7030 (39%) 847 (34%) 929 (34%) 406 (19%) 1084 (69%) 1051 (46%) 1616 (46%) 1097 (33%) NA
LVEF ·· ·· ·· ·· ·· ·· ·· ·· <0·0001
<40% 7600 (50%) 1191 (55%) 805 (34%) 1016 (57%) 592 (49%) 1125 (58%) 1399 (52%) 1472 (50%) NA
40–49% 3009 (20%) 367 (17%) 641 (27%) 380 (21%) 137 (11%) 411 (21%) 506 (19%) 567 (19%) NA
≥50% 4505 (30%) 592 (28%) 955 (40%) 387 (22%) 492 (40%) 410 (21%) 775 (29%) 894 (31%) NA
Missing 2988 (17%) 375 (15%) 360 (13%) 389 (18%) 344 (22%) 346 (15%) 809 (23%) 365 (11%) NA
(Table 1 continues on next page)
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Total 
(N=18 102)
Central and 
South America 
(n=2525)
Eastern 
Europe 
(n=2761)
Eastern 
Mediterranean 
region and 
Africa (n=2172)
North America 
(n=1565)
Southeast 
Asia (n=2292)
Western 
Europe 
(n=3489)
Western 
Pacific 
(n=3298)
p value*
(Continued from previous page)
Signs and symptoms
Dyspnoea at rest 13 260 (83%) 1838 (83%) 2320 (87%) 1844 (91%) 595 (71%) 1738 (86%) 2435 (77%) 2490 (81%) <0·0001
Missing 2088 (12%) 318 (13%) 86 (3%) 140 (6%) 723 (46%) 260 (11%) 326 (9%) 235 (7%) NA
Paroxysmal nocturnal dyspnoea 8864 (64%) 1116 (64%) 1681 (69%) 1538 (83%) 291 (40%) 969 (53%) 1437 (59%) 1832 (65%) <0·0001
Missing 4189 (23%) 776 (31%) 311 (11%) 323 (15%) 835 (53%) 454 (20%) 1034 (30%) 456 (14%) NA
Peripheral oedema 11 080 (69%) 1819 (77%) 2078 (77%) 1388 (67%) 923 (73%) 900 (50%) 2280 (73%) 1692 (60%) <0·0001
Missing 1944 (11%) 154 (6%) 45 (2%) 113 (5%) 296 (19%) 477 (21%) 370 (11%) 489 (15%) NA
Pulmonary rales 10 011 (67%) 1585 (70%) 1954 (72%) 1747 (85%) 372 (33%) 1129 (68%) 1608 (63%) 1616 (64%) <0·0001
Missing 3224 (18%) 268 (11%) 57 (2%) 113 (5%) 439 (28%) 627 (27%) 943 (27%) 777 (24%) NA
JVP 6145 (58%) 1112 (64%) 899 (59%) 1035 (66%) 575 (59%) 1012 (64%) 798 (49%) 714 (48%) <0·0001
Missing 7574 (42%) 793 (31%) 1240 (45%) 594 (27%) 590 (38%) 707 (31%) 1846 (53%) 1804 (55%) NA
Comorbidities
Hypertension 11 547 (64%) 1716 (68%) 2214 (80%) 1304 (60%) 1208 (77%) 1091 (47%) 2195 (63%) 1819 (55%) <0·0001
Missing 20 (<1%) 4 (<1%) 0 1 (<1%) 1 (<1%) 3 (<1%) 9 (<1%) 2 (<1%) NA
Atrial fibrillation or flutter 5637 (31%) 681 (27%) 1304 (47%) 459 (21%) 595 (38%) 188 (8%) 1594 (46%) 816 (25%) <0·0001
Missing 20 (<1%) 4 (<1%) 0 1 (<1%) 1 (<1%) 3 (<1%) 9 (<1%) 2 (<1%) NA
Type 2 diabetes 6658 (37%) 787 (31%) 911 (33%) 1019 (47%) 652 (42%) 957 (42%) 1279 (37%) 1053 (32%) <0·0001
Missing 6 (<1%) 0 1 (<1%) 2 (<1%) 0 0 1 (<1%) 2 (<1%) NA
Chronic kidney disease 3638 (20%) 439 (17%) 629 (23%) 382 (18%) 526 (34%) 239 (10%) 918 (26%) 505 (15%) <0·0001
Missing 6 (<1%) 0 1 (<1%) 2 (<1%) 0 0 1 (<1%) 2 (<1%) NA
Anaemia 8453 (47%) 998 (40%) 978 (35%) 1124 (52%) 1055 (67%) 1236 (54%) 1797 (52%) 1265 (38%) <0·0001
Missing 5 (<1%) 0 1 (<1%) 2 (<1%) 0 0 0 2 (<1%) NA
Valvular heart disease 3552 (20%) 517 (20%) 832 (30%) 322 (15%) 263 (17%) 178 (8%) 1006 (29%) 434 (13%) <0·0001
Missing 20 (<1%) 4 (<1%) 0 1 (<1%) 1 (<1%) 3 (<1%) 9 (<1%) 2 (<1%) NA
Coronary artery disease 8710 (48%) 826 (33%) 1714 (62%) 1121 (52%) 731 (47%) 1172 (51%) 1530 (44%) 1616 (49%) <0·0001
Missing 19 (<1%) 4 (<1%) 0 1 (<1%) 1 (<1%) 2 (<1%) 9 (<1%) 2 (<1%) NA
Cause
Ischaemic 6034 (40%) 594 (31%) 1148 (45%) 864 (48%) 336 (27%) 715 (37%) 1101 (40%) 1276 (44%) NA
Hypertension 2812 (19%) 428 (22%) 553 (22%) 338 (19%) 302 (25%) 468 (24%) 366 (13%) 357 (12%) NA
Cardiomyopathy 2854 (19%) 333 (17%) 300 (12%) 261 (15%) 362 (30%) 449 (23%) 501 (18%) 648 (23%) NA
Valvular 1930 (13%) 317 (16%) 363 (14%) 232 (13%) 90 (7%) 135 (7%) 492 (18%) 301 (11%) NA
Other 1491 (9%) 279 (14%) 182 (7%) 96 (5%) 138 (11%) 174 (9%) 322 (11%) 300 (10%) NA
Missing 2981 (16%) 574 (23%) 215 (8%) 381 (18%) 337 (22%) 351 (15%) 707 (20%) 416 (13%) NA
Medication at discharge (patients with HFrEF)
ACEI or ARB 5317 (68%) 856 (68%) 616 (75%) 739 (71%) 363 (60%) 637 (56%) 1048 (73%) 1058 (71%) NA
Missing 238 (3%) 73 (6%) 20 (2%) 35 (3%) 17 (3%) 22 (2%) 41 (3%) 30 (2%) NA
Diuretics (any) 6548 (84%) 951 (76%) 744 (90%) 904 (86%) 527 (87%) 945 (83%) 1299 (90%) 1178 (79%) NA
Missing 232 (3%) 70 (6%) 19 (2%) 35 (3%) 17 (3%) 22 (2%) 39 (3%) 30 (2%) NA
Loop diuretics 6466 (83%) 942 (75%) 731 (89%) 898 (86%) 522 (86%) 941 (82%) 1285 (89%) 1147 (77%) NA
Missing 238 (3%) 73 (6%) 20 (2%) 35 (3%) 17 (3%) 22 (2%) 41 (3%) 30 (2%) NA
Thiazides 235 (3%) 26 (2%) 58 (7%) 19 (2%) 4 (1%) 7 (1%) 70 (5%) 51 (3%) <0·0001
Missing 238 (3%) 73 (6%) 20 (2%) 35 (3%) 17 (3%) 22 (2%) 41 (3%) 30 (2%) NA
β blocker 5748 (74%) 982 (79%) 686 (83%) 755 (72%) 493 (81%) 564 (49%) 1225 (85%) 1043 (70%) NA
Missing 238 (3%) 73 (6%) 20 (2%) 35 (3%) 17 (3%) 22 (2%) 41 (3%) 30 (2%) NA
MRA 4585 (59%) 861 (69%) 617 (75%) 504 (48%) 255 (42%) 421 (37%) 873 (61%) 1054 (71%) <0·0001
Missing 232 (3%) 70 (6%) 19 (2%) 35 (3%) 17 (3%) 22 (2%) 39 (3%) 30 (2%) NA
(Table 1 continues on next page)
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Outcomes
Standardised follow-up calls were done at 6 months and 
1 year. Follow-up information from study participants 
was collected via telephone interviews unless a regular 
follow-up visit was planned at the investigator’s site for 
routine care. Vital status was supplemented by national 
reporting databases where available.12 Cause of death was 
ascertained by the local investigators and classified as 
cardiovascular, non-cardiovascular, or unknown.
Statistical analysis
We report post-discharge mortality according to region, 
country income level, and country income distribution. 
Geographical groupings of the 44 participating countries 
were determined using a modification of the WHO 
classification into seven regions (appendix p 1). The final 
categories were selected to enable meaningful com-
parisons among geographical regions and to provide 
balance between the number of countries and patients in 
each region (appendix p 1). Countries were also grouped 
by income level, based on the World Bank classification 
(appendix p 1). We used the gross national income in 2017 
as a reference.13 The effect of income inequality was 
studied using the Gini coefficient, with zero (0%) 
representing absolute income equality and one (100%) 
indicating absolute income inequality. For most countries, 
the Gini coefficients were obtained from the UN 
Development Programme.14 Data from 2003 were used to 
account for a potential lag effect, because current health 
is more likely to be related to previous rather than 
contemporary income inequality.15 If the Gini coefficient 
for 2003 was unavailable, the value closest to 2003 was 
used. In secondary analyses, we regrouped countries in 
Asia into northeast (China, Japan, Korea, and Taiwan), 
southeast (Indonesia, Malaysia, Thailand, and Vietnam), 
Total 
(N=18 102)
Central and 
South America 
(n=2525)
Eastern 
Europe 
(n=2761)
Eastern 
Mediterranean 
region and 
Africa (n=2172)
North America 
(n=1565)
Southeast 
Asia (n=2292)
Western 
Europe 
(n=3489)
Western 
Pacific 
(n=3298)
p value*
(Continued from previous page)
Medication at 6-month follow-up
ACEi or ARB† 9189 (59%) 1272 (61%) 1704 (69%) 1140 (63%) 712 (53%) 876 (44%) 1923 (64%) 1562 (55%) <0·0001
β blocker† 10 437 (67%) 1400 (67%) 1883 (76%) 1222 (68%) 1057 (78%) 925 (47%) 2330 (78%) 1620 (57%) <0·0001
Diuretics† 11 176 (67%) 1345 (65%) 1923 (78%) 1376 (63%) 1078 (80%) 1326 (67%) 2516 (84%) 1614 (57%) <0·0001
MRA† 6608 (43%) 9539 (45%) 1289 (52%) 573 (32%) 469 (35%) 528 (27%) 1411 (47%) 1399 (50%) <0·0001
Length of stay, days† 8 (5–12) 8 (5–14) 9 (6–13) 6 (4–10) 6 (4–10) 6 (4–8) 9 (6–13) 9 (7–14) <0·0001
1-year mortality 3461 (20%) 547 (23%) 439 (16%) 472 (22%) 324 (21%) 470 (21%) 668 (20%) 541 (17%) <0·0001
Hospitalisation
Hospitalised for any cause 6674 (38%) 799 (33%) 1062 (39%) 773 (36%) 955 (62%) 428 (19%) 1583 (47%) 1074 (34%) <0·0001
Hospitalised for heart failure 3940 (22%) 482 (20%) 654 (24%) 478 (23%) 626 (41%) 240 (11%) 826 (24%) 634 (20%) <0·0001
Death or heart failure 
hospitalisation
6928 (39%) 972 (40%) 1038 (38%) 913 (43%) 830 (54%) 673 (30%) 1395 (41%) 1107 (35%) <0·0001
Data are n (%), unless otherwise stated. BMI=body-mass index. DCHF=decompensated chronic heart failure. NYHA=New York Heart Association. LVEF=left ventricular ejection fraction. JVP=jugular venous 
pressure. ACEi=angiotensin-converting enzyme inhibitor. ARB=angiotensin receptor blocker. MRA=mineralocorticoid receptor antagonist. *All comparisons p<0·001. †No data missing.
Table 1: Differences between patients according to region
Total 
(n=18 102)
Lower middle 
income 
(n=3025)
Upper middle 
income 
(n=7521)
High income 
(n=7556)
p value 
for linear 
trend*
Demographics
Sex†
Female 7003 (39%) 1083 (36%) 3042 (40%) 2878 (38%) NA
Male 11 099 (61%) 1942 (64%) 4479 (60%) 4678 (62%) 0·374
Age, years† 67 (57–77) 61 (52–70) 67 (57–76) 71 (60–80) <0·0001
BMI, kg/m² 27 (24–32) 24 (22–27) 27 (24–31) 28 (24–34) <0·0001
Missing 9396 (52%) 1940 (64%) 4427 (59%) 3029 (40%) NA
Obesity ·· ·· ·· ·· <0·0001
BMI ≤30 kg/m² 2850 (16%) 133 (4%) 892 (12%) 1825 (24%) NA
Missing 9396 (52%) 1940 (64%) 4427 (59%) 3029 (40%) NA
Race† ·· ·· ·· ·· <0·0001
White 9409 (52%) 345 (11%) 3776 (50%) 5288 (70%) NA
Black 852 (5%) 2 (<1%) 119 (2%) 731 (10%) NA
Asian 5642 (31%) 2497 (83%) 2111 (28%) 1034 (14%) NA
Native American 364 (2%) 0 285 (4%) 79 (1%) NA
Pacific Islander 7 (<1%) 0 3 (<1%) 4 (<1%) NA
Other 1828 (10%) 181 (6%) 1227 (16%) 420 (6%) NA
Heart failure† ·· ·· ·· ·· <0·0001
DCHF 10 353 (57%) 973 (32%) 4634 (62%) 4746 (63%) NA
Ischaemic aetiology 6034 (33%) 1159 (38%) 2746 (37%) 2129 (28%) <0·0001
Missing 2981 (16%) 346 (11%) 1002 (13%) 1633 (22%) NA
NYHA class ·· ·· ·· ·· <0·0001
I 837 (5%) 123 (4%) 354 (5%) 360 (5%) NA
II 3226 (18%) 479 (16%) 1537 (20%) 1210 (16%) NA
III 4959 (27%) 682 (23%) 2536 (34%) 1741 (23%) NA
IV 2050 (11%) 431 (14%) 1130 (15%) 489 (6%) NA
Missing 7030 (39%) 1310 (43%) 1964 (26%) 3756 (50%) NA
(Table 2 continues on next page)
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and south Asia (India), similar to an earlier publication.2 
For comparisons between groups the one-way analysis of 
variance, χ² test, or Mann-Whitney U-test was used for 
normally distributed continuous variables, categorical 
variables, and non-normally distributed continuous 
variables, respectively. Differences in clinical charac-
teristics according to country income were tested using 
a non-parametric test for linear trend. To test for 
differences in survival between regions, income classes, 
and tertiles of Gini coefficients, the log-rank test was 
used. Differences were graphically depicted using Kaplan-
Meier curves. Univariable and multivariable regression of 
factors associated with 1-year mortality was done using 
Cox regression analyses. Variables included for 
multivariable analyses were chosen based on previous 
reports of strong associations with mortality in studies of 
acute heart failure and expert clinical opinion.16 
Collinearity of independent variables was checked by 
assessing the variance inflation factor, where none of the 
variables exceeded the suggested maximum level of ten.17 
Given the large number of patients enrolled and the 
multiple comparisons, the investigators viewed p values 
considering the relative effect sizes and clinically 
important differences. Because missingness was non-
random, but rather part of obtaining an understanding of 
regional differences in initial data, we did not perform 
multiple imputation, but transformed the variable to 
include missing values. In multivariable analyses, we 
classified countries by seven geographic regions. Because 
classifi cation by region alone might not capture important 
differences between countries, we also classified countries 
using three levels of country income (low [≤US$3955 per 
capita], middle [$3956–12 235], and high [>$12 235]) and 
by tertiles of Gini index and included these in the 
multivariable models separately. We checked the pro-
portionality hazards assumption for Cox models using 
statistical tests and graphical diagnostics on the basis of 
the Schoenfeld residuals. In secondary analyses, we did 
Cox regression while clustering the estimates around 
countries to obtain more robust estimates. The STROBE 
statement checklist is included in the appendix (p 8). All 
analyses were done in STATA, version 15.0, or R, 
version 3.4.2. A two-sided p value of less than 0·05 was 
considered statistically significant.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Over 32 months, between July 23, 2014, and March 24, 
2017, at 358 sites in 44 countries, 41 793 patients were 
screened, and 22 988 of whom were excluded because they 
did not fulfil the inclusion or exclusion criteria (7725, 
Total 
(n=18 102)
Lower middle 
income 
(n=3025)
Upper middle 
income 
(n=7521)
High income 
(n=7556)
p value 
for linear 
trend*
(Continued from previous page)
LVEF ·· ·· ·· ·· <0·0001
<40% 7600 (42%) 1343 (44%) 3140 (42%) 3117 (41%) NA
40–49% 3009 (17%) 544 (18%) 1431 (19%) 1034 (14%) NA
>50% 4505 (25%) 542 (18%) 2121 (28%) 1842 (24%) NA
Missing 2988 (17%) 596 (20%) 829 (11%) 1563 (21%) NA
Signs and symptoms
Dyspnoea at rest 13 260 (73%) 2281 (75%) 6050 (80%) 4929 (65%) <0·0001
Missing 2088 (12%) 311 (10%) 503 (7%) 1274 (17%) NA
Paroxysmal nocturnal 
dyspnoea
8864 (49%) 1390 (46%) 4685 (62%) 2789 (37%) <0·0001
Missing 4189 (23%) 648 (21%) 1083 (14%) 2458 (33%) NA
Peripheral oedema 11 080 (61%) 1270 (42%) 5166 (69%) 4644 (61%) <0·0001
Missing 1944 (11%) 536 (18%) 345 (5%) 1063 (14%) NA
Pulmonary rales 10 011 (55%) 1674 (55%) 5037 (67%) 3300 (44%) <0·0001
Missing 3224 (18%) 656 (22%) 519 (7%) 2049 (27%) NA
JVP 6145 (34%) 1253 (41%) 2629 (35%) 2263 (30%) <0·0001
Missing 7574 (42%) 1019 (34%) 2977 (40%) 3578 (47%) NA
Comorbidities
Hypertension 11 547 (64%) 1512 (50%) 4992 (66%) 5043 (67%) <0·0001
Missing 20 (<1%) 4 (<1%) 3 (<1%) 13 (<1%) NA
Atrial fibrillation or 
flutter
5637 (31%) 277 (9%) 2375 (32%) 2985 (40%) <0·0001
Missing 20 (<1%) 4 (<1%) 3 (<1%) 13 (<1%) NA
COPD or asthma 2587 (14%) 224 (7%) 1045 (14%) 1318 (17%) <0·0001
Missing 6 (<1%) 1 (<1%) 4 (<1%) 1 (<1%) NA
Type 2 diabetes 6658 (37%) 1187 (39%) 2585 (34%) 2886 (38%) 0·496
Missing 6 (<1%) 1 (<1%) 4 (<1%) 1 (<1%) NA
Chronic kidney disease 3638 (20%) 325 (11%) 1332 (18%) 1981 (26%) <0·0001
Missing 6 (<1%) 1 (<1%) 4 (<1%) 1 (<1%) NA
Liver disease 542 (3%) 30 (1%) 245 (3%) 267 (4%) <0·0001
Missing 6 (<1%) 1 (<1%) 4 (<1%) 1 (<1%) NA
Anaemia 8453 (47%) 1552 (51%) 2829 (38%) 4072 (54%) <0·0001
Missing 5 (<1%) 1 (<1%) 4 (<1%) 0 NA
Valvular heart disease 3552 (20%) 269 (9%) 1566 (21%) 1717 (23%) <0·0001
Missing 20 (<1%) 4 (<1%) 3 (<1%) 13 (<1%) NA
Coronary artery disease 8710 (48%) 1629 (54%) 3831 (51%) 3250 (43%) <0·0001
Missing 19 (<1%) 3 (<1%) 3 (<1%) 13 (<1%) NA
Cause ·· ·· ·· ·· <0·0001
Ischaemic 6034 (40%) 594 (31%) 1148 (45%) 864 (48%) NA
Hypertension 2812 (19%) 428 (22%) 553 (22%) 338 (19%) NA
Cardiomyopathy 2854 (19%) 333 (17%) 300 (12%) 261 (15%) NA
Valvular 1930 (13%) 317 (16%) 363 (14%) 232 (13%) NA
Other 1491 (9%) 279 (14%) 182 (7%) 96 (5%) NA
Missing 2981 (16%) 346 (11%) 1002 (13%) 1633 (22%) NA
Medication at discharge
ACEi or ARB 11 895 (66%) 1815 (60%) 5105 (68%) 4975 (66%) NA
Missing 72 (<1%) 16 (1%) 42 (1%) 14 (<1%) NA
Diuretics 15 153 (84%) 2324 (77%) 6116 (81%) 6713 (89%) <0·0001
Missing 72 (<1%) 16 (1%) 42 (1%) 14 (<1%) NA
(Table 2 continues on next page)
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18·4%) or did not provide informed consent (7628, 18·3%; 
appendix p 1). Patients screened but not enrolled were 
similar in age and sex compared with those enrolled. Of 
18 553 patients who gave consent, 451 died during the 
index admission, and 18 102 were discharged. The median 
age was 67 years (IQR 57–77) and 11 099 (61%) of 
18 102 patients in the total discharge population were 
men (table 1). The median age ranged from 61 years 
(IQR 53–70) in southeast Asia to 75 years (65–81) in 
western Europe. Of the total discharge population, most 
patients (10 353 [57%] of 18 102) were admitted with an 
episode of decompensated chronic heart failure (DCHF), 
with the highest proportion in North America (1249 [80%] 
of 1565) and lowest in southeast Asia (487 [21%] of 2292). 
Half of the total discharge population had HFrEF. HFpEF 
was most often reported in North America (492 [40%] of 
1221) and eastern Europe (955 [40%] of 2401). The comor-
bidity burden showed strong regional heterogeneity, with 
a high prevalence of hypertension in eastern Europe 
(2214 [80%] of 2761) and North America (1208 [77%] of 
1564), whereas atrial fibrillation was particularly common 
among patients from western Europe (1594 [46%] of 3480). 
Type 2 diabetes was most common among patients from 
eastern Mediterranean region and Africa (1019 (47%) of 
2172, whereas chronic kidney disease (526 [34%] of 1565) 
and anaemia (1055 [67%] of 1550) were more common 
among patients from North America. Patients from 
eastern Europe and Central and South America were 
more often on angiotensin-converting enzyme inhibitors 
(ACEi) or angiotensin receptor blockers (ARBs), 
β blockers, or minera locorticoid receptor antagonists 
(MRAs) at discharge and at 6-month follow-up compared 
with other regions. Patients from southeast Asia (median 
6 days [IQR 4–8]) and North America (6 [4–10]) had the 
shortest length of stay, and eastern Europe (9 [6–3]), 
western Europe (9 [6–13]), and western Pacific (9 [7–14]) 
the longest. Country characteristics of Asian countries 
grouped into northeast, southeast, and south Asia are 
shown in the appendix (p 4).
Classifying countries according to income level, most 
patients were either from high (7556 [42%] of 18 102) or 
upper-middle-income (7521 [42%] of 18 102) countries 
(table 2). Compared with patients from higher-income 
countries, patients from lower-middle-income countries 
were almost a decade younger (61 years [IQR 52–70] vs 
71 years [60–80]), with a lower body-mass index (BMI; 
24 kg/m² [22–27] vs 28 [24–34]) and were more often 
admitted with a first episode of heart failure. Despite 
their relative youth, patients from lower-middle-income 
countries were in a worse (ie, higher) New York Heart 
Association class class, more often had HFrEF, and 
generally had worse signs and symptoms. Except for 
coronary artery disease and diabetes, the comorbidity 
burden was lower in lower-middle-income countries. 
Patients from lower-middle-income countries were 
more likely to be admitted to an intensive care unit or 
critical care unit during admission to hospital. 
At discharge and 6-month follow-up, prescription rates 
of ACEi or ARBs, β blockers, and MRAs were lower in 
lower-middle-income countries compared with higher-
income countries.
Of the 18 102 patients discharged, vital status could 
not be ascertained in 470 patients (3%) at 1 year. Of 
17 632 patients, 3461 (20%) died within 1 year. Patients 
from eastern Europe had the lowest 1-year mortality 
(439 [16%] of 2724) and those from eastern Mediterranean 
and Africa (472 [22%] of 2124) and Latin America 
(547 [22%] of 2419) had the highest, with large intercountry 
variation ranging from 10% in Bulgaria to 32% in 
Indonesia (figures 1, 2). Age-adjusted and heart failure 
diagnosis (new onset vs DCHF)-adjusted mortality were 
higher in patients from lower-income countries (26%) 
compared with middle-income (20%) and higher-income 
(17%) countries. Patients from regions with greater 
income inequality had worse mortality (figure 2). Most 
deaths were due to cardiovascular causes (2076 [60%] of 
3461), with the proportion being highest in eastern 
Europe (310 [71%] of 439; figure 3). In North America, a 
large proportion of deaths were not classified. Causes of 
death stratified by region are listed in the appendix (p 7). 
The proportion of all deaths was attributable to 
Total 
(n=18 102)
Lower middle 
income 
(n=3025)
Upper middle 
income 
(n=7521)
High income 
(n=7556)
p value 
for linear 
trend*
(Continued from previous page)
Loop diuretics 14 733 (81%) 2279 (75%) 5847 (78%) 6607 (87%) <0·0001
Missing 72 (<1%) 16 (1%) 42 (1%) 14 (<1%) NA
Thiazides 833 (5%) 71 (2%) 440 (6%) 322 (4%) 0·041
Missing 72 (<1%) 16 (1%) 42 (1%) 14 (<1%) NA
β blocker 13 043(72%) 1498 (50%) 5583 (74%) 5962 (79%) <0·0001
Missing 72 (<1%) 16 (1%) 42 (1%) 14 (<1%) NA
MRA 8852 (49%) 1149 (38%) 4164 (55%) 3539 (47%) 0·001
Missing 72 (<1%) 16 (1%) 42 (1%) 14 (<1%) NA
Medication at 6-month follow-up
ACEi or ARB† 9189 (59%) 1332 (53%) 3937 (61%) 3920 (60%) <0·0001
β blocker† 10 437 (67%) 1199 (47%) 4361 (68%) 4877 (75%) <0·0001
Diuretics† 11 176 (72%) 1583 (62%) 4488 (70%) 5105 (79%) <0·0001
MRA† 6608 (43%) 752 (30%) 3047 (47%) 2809 (43%) <0·0001
Length of stay, days† 8 (5–12) 6 (4–9) 9 (6–13) 8 (5–12) <0·0001
1-year mortality 3461 (20%) 619 (20%) 1457 (19%) 1385 (18%) 0·009
Hospitalisation
Hospitalised for any 
cause at 1 year
6674 (37%) 534 (18%) 2674 (36%) 3466 (46%) <0·0001
Hospitalised for heart 
failure
3940 (22%) 316 (10%) 1667 (22%) 1957 (26%) <0·0001
Death or heart failure 
hospitalisation
6928 (38%) 894 (30%) 2955 (39%) 3079 (41%) <0·0001
Data are n (%) or median (IQR), unless otherwise stated. BMI=body-mass index. DCHF=decompensated chronic heart 
failure. NYHA=New York Heart Association. LVEF=left ventricular ejection fraction. JVP=jugular venous pressure. 
COPD=chronic obstructive pulmonary disease. ACEi=angiotensin-converting enzyme inhibitor. ARB=angiotensin 
receptor blocker. MRA=mineralocorticoid receptor antagonist. *All comparisons p<0·001. †No data missing. 
Table 2: Differences between patient characteristics according to country income level
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cardiovascular causes was higher in countries with lower 
income (65% vs 50%; p<0·001) and, to a lesser extent, 
greater income inequality (60% vs 58%; p<0·001).
Regional differences in 1-year mortality remained after 
adjusting for prognostic indicators, with patients from 
lower-income regions (HR 1·58, 95% CI 1·41–1·78; 
p<0·0001) and greater income inequality (1·25, 1·13–1·38; 
p<0·0001) being more likely to die (table 3). We found an 
interaction between regional income level and heart 
failure subtype (pinteraction<0·001; appendix p 7), where 
differences in mortality across income levels were 
observed for patients with HFrEF but not for those with 
HFpEF (figure 3). There was also an interaction between 
income inequality and regional income where patients 
from low-income countries with a low Gini index had the 
worst outcomes overall and patients from high-income 
countries with a low Gini index did better (1-year mortality 
29% vs 17%; p<0·0001). On a continuous scale, a 10-point 
increase in Gini index was associated with greater post-
discharge mortality (HR 1·16, 95% CI 1·11–1·21; p<0·001) 
in our multivariable model. Similarly, an increase of 
US$5000 in GDP was associated with better post-
discharge mortality (0·96, 0·95–0·98; p<0·001) after 
multivariable adjustments. In secondary analyses, we 
obtained more robust variance estimates using country as 
the clustering variable. Compared with higher-income 
countries, patients from upper-middle-income (1·22, 
1·12–1·33) and lower-middle-income (1·58, 1·41–1·78) 
countries had worse outcomes. Similarly, patients from 
southeast Asia had the worst outcomes (2·02, 1·73–2·37), 
followed by eastern Mediterranean and Africa (1·74, 
1·50–2·01) and Central and South America (1·69, 
1·47–1·94). Results remained similar for Gini tertiles, 
where patients from the highest tertile of disparity had 
the worst outcomes (1·32, 1·21–1·45) compared with 
patients from the lowest tertile. No significant interaction 
(p=0·347) was observed between Gini coefficient and 
income class for 1-year all-cause mortality.
Across all regions, important predictors of worse 1-year 
mortality were old age, lower systolic blood pressure, 
anaemia, chronic kidney disease, valvular heart disease, 
and not receiving ACEi or β blockers at discharge 
(table 3). Compared with patients with HFrEF, patients 
with HFmrEF (HR 0·82, 95% CI 0·74–0·90), and 
HFpEF (0·67, 0·61–0·74) had better outcomes.
Discussion
People with greater socioeconomic deprivation are at a 
higher risk for non-communicable disease in general, 
and heart failure in particular, with a younger age at 
onset and worse outcomes.18 REPORT-HF is the first 
international registry to collect the same data on patients 
with acute heart failure simultaneously from all 
inhabited world regions, and shows substantial variation 
in post-discharge mortality. Patients with HFrEF from 
countries with lower incomes were less likely to receive 
GDMT, both at discharge and at 6 months and had a 
higher 1-year mortality despite being almost a decade 
younger than patients from high-income countries. 
Conversely, patients with HFpEF had a somewhat 
overall better prognosis with much less variation 
according to national income or income inequality. 
Differences in the quality of care and availability of 
GDMT might account for the variability in outcome for 
HFrEF. Scarcity of treatments known to improve 
prognosis for HFpEF might explain why variations in 
access to care have little effect on the outcome of 
HFpEF.
Figure 1: World map showing age, heart failure diagnosis, and New York Heart Association class-adjusted percentage of patients who died within 1 year
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Figure 2: Kaplan Meier curves showing 1-year all-cause mortality rate stratified to region (A), country income level (B), and tertiles of income inequality (C)
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The 1-year mortality in REPORT-HF (20% overall, 
13% in eastern Europe, and 18% in western Europe) is 
consistent with that observed in the European Society of 
Cardiology Heart Failure Pilot19 and long-term registry20 
(ESC-HF-LT; 23·4%). In the National Audit of England 
and Wales, among more than 150 000 patients enrolled 
between 2014 and 2018, the 1-year mortality was strongly 
related to age at around 20% for those aged 65–74 years.21 
In North America, 1-year mortality in REPORT-HF 
was 21%, which is lower than observed in Get-With-The-
Guidelines (GWTG; 36%) and OPTIMIZE-HF (35%) 
registries. However, these registries excluded people 
younger than age 65 years for these analyses, hence 
the average age of their patients was almost two 
decades older than patients from North America in 
REPORT-HF.22,23 Further informed consent was not 
required in GWTG or OPTIMIZE. In Asia, data from the 
ASIAN-HF registry showed a 1-year all-cause mortality of 
13% for patients with either HFpEF or HFrEF enrolled 
as in-patients.24 Patients with acute heart failure enrolled 
in the Trivandrum Heart Failure Registry25 showed a 
1-year mortality of 30%. Whether these data are 
representative of other Indian states is uncertain. 
Mortality in REPORT-HF for Latin America (23%), 
Univariable Multivariable*
Demographics
Age (per 10 years) 1·17 (1·15–1·21), <0·001 1·19 (1·15–1·22), <0·001
Sex
Female 1 (ref) 1 (ref)
Men 1·04 (0·97–1·11), 0·291 0·99 (0·92–1·07), 0·808
Clinical characteristics
Systolic blood 
pressure (above or 
below median)
0·60 (0·55–0·64), <0·001 0·65 (0·60–0·70), <0·001
DCHF 1·67 (1·56–1·80), <0·001 1·43 (1·32–1·55), <0·001
NYHA class
I 1 (ref) 1 (ref)
II 1·43 (1·24–1·64), <0·001 1·36 (1·19–1·57), <0·001
III 1·91 (1·65–2·20), <0·001 1·85 (1·59–2·16), <0·001
IV 3·07 (2·56–3·69), <0·001 2·62 (2·16–3·18), <0·001
Peripheral oedema 1·41 (1·30–1·52), <0·001 1·24 (1·14–1·34), <0·001
Diabetes 1·16 (1·08–1·24), <0·001 1·03 (0·96–1·11), 0·322
Coronary artery 
disease
1·20 (1·12–1·28), <0·001 1·04 (0·96–1·12), 0·343
Atrial fibrillation 1·18 (1·10–1·26), <0·001 1·01 (0·93–1·08), 0·798
Anaemia 1·93 (1·79–2·09), <0·001 1·53 (1·41–1·66), <0·001
Chronic kidney 
disease
1·57 (1·45–1·70), <0·001 1·18 (1·09–1·28), <0·001
Valvular heart 
disease
1·38 (1·27–1·50), <0·001 1·17 (1·07–1·27), <0·001
LVEF type
<40% 1 (ref) 1 (ref)
40–50% 0·83 (0·76–0·92), <0·001 0·82 (0·74–0·90), <0·001
>50% 0·71 (0·65–0·77), <0·001 0·67 (0·61–0·74), <0·001
(Table 3 continues in next column)
Figure 3: Mortality rates after 1-year stratified to heart failure subtype and country income level
HFrEF=heart failure with reduced ejection fraction. HFmrEF=heart failure with mid-range ejection fraction. 
HFpEF=heart failure with preserved ejection fraction.
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Cause of death
Univariable Multivariable*
(Continued from previous column)
Regional or socioeconomic factors
Region
Eastern Europe 1 (ref) 1 (ref)
Central and 
South America
1·46 (1·29–1·66), <0·001 1·69 (1·47–1·94), <0·001
Eastern 
Mediterranean 
and Africa
1·44 (1·27–1·65), <0·001 1·74 (1·50–2·01), <0·001
North America 1·35 (1·17–1·56), <0·001 1·30 (1·11–1·52), <0·001
Southeast Asia 1·33 (1·17–1·52), <0·001 2·02 (1·73–2·37), <0·001
Western Europe 1·25 (1·11–1·41), <0·001 1·17 (1·02–1·33), 0·023
Western Pacific 1·07 (0·94–1·21), 0·285 1·22 (1·07–1·40), 0·004
Country income
High income 1 (ref) 1 (ref)
Upper-middle 
income
1·06 (0·98–1·14), 0·151 1·22 (1·12–1·33), <0·001
Lower-middle 
income
1·14 (1·03–1·25), 0·008 1·58 (1·41–1·78), <0·001
Income inequality
Low 1 (ref) 1 (ref)
Middle 1·09 (1·01–1·19), 0·046 1·04 (0·95–1·14), 0·0378
High 1·19 (1·08–1·29), <0·001 1·25 (1·13–1·38), <0·001
Medication or quality of care
Length of stay 
(above or below 
median)
1·45 (1·35–1·55), <0·001 1·37 (1·27–1·47), <0·001
β blocker at 
discharge
0·73 (0·68–0·78), <0·001 0·77 (0·71–0·83), <0·001
ACEi or ARB at 
discharge
0·60 (0·56–0·64), <0·001 0·73 (0·68–0·78), <0·001
Data are HR (95% CI), p value. DCHF=decompensated chronic heart failure. 
NYHA=New York Heart Association. LVEF=left ventricular ejection fraction. 
ACEi=ACE inhibitor. ARB=angiotensin receptor blocker. *Corrected for all variables 
in table 3 except for Gini tertiles and income class. Estimates for Gini tertiles and 
income class are corrected for all variables except for region; income and region; 
Gini, respectively.
Table 3: Predictors of 1-year mortality
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southeast Asia (23%), and China (17%) were consistent 
with or exceeded those reported for patients enrolled in 
hospital in INTER-CHF.4 We suggest that any differences 
in mortality in other registries and those in REPORT-HF 
might be due to differences in centres included, 
proportion of patients dwelling in rural areas, and the 
need for patients to consent to partici pation. Post-hoc 
analyses from two clinical trials26,27 have found similar 
results to those of REPORT-HF with respect to socio-
economic deprivation and mortality. However, 
REPORT-HF not only is much larger, but it also includes 
a more diverse population, with few inclusion and 
exclusion criteria, no intervention that might influence 
patient participation, and many more countries and 
regions. Despite being a decade younger and having a 
more favourable risk profile, patients in low-to-middle-
income countries had a 3% higher 1-year crude mortality. 
After correcting for age and other risk factors, the excess 
mortality in countries of low and middle income 
appeared much larger. Despite the association between 
country income level and post-discharge outcomes, 
there were a number of countries that had lower 
post-discharge mortality than predicted by their low 
GDP. This suggests other unmeasured factors beyond 
GDP might effect post-discharge mortality, including 
differences in country health-care financing and delivery 
systems, local standards and practices, as well as 
compliance with guideline-directed medical therapies 
and their up-titration. Our multivariable models did not 
fully explain differences in post-discharge mortality, 
suggesting that beyond the variables captured, other 
factors might play a role, which deserve further study.
Strong predictors of post-discharge mortality in 
REPORT-HF included age, systolic blood pressure, 
anaemia, renal function, presence of valvular heart 
disease, and LVEF phenotype, which generally confirms 
prior knowledge.16 In REPORT-HF, patients with HFpEF 
had considerably better outcomes than those with 
HFrEF.28 Analyses of cohorts with chronic heart failure 
generally show that, compared with those with HFrEF, 
patients with HFpEF have a better prognosis,28 and this is 
true for those of either European or Asian origin.29 The 
lower mortality with HFpEF in REPORT-HF might reflect 
patient selection incurred by the consent procedure. Older 
patients hospitalised with heart failure often have multiple 
precipitating factors and other diagnoses all contributing 
to the need for admission. Multimorbid patients might 
be less likely to be asked and less likely to consent to 
participation but also have the worst outcome. Yet, despite 
being a decade younger and having a more favourable risk 
profile, patients with HFpEF from low to middle-income 
countries had a similar mortality at 1 year compared with 
patients with HFpEF from high-income countries. 
Although all-cause mortality for patients with acute heart 
failure might be similar for those with HFrEF and HFpEF, 
causes of death might differ; patients with HFrEF might 
be more likely to die from cardiovascular events whereas 
patients with HFpEF might have a broad and complex 
range of problems that conspire together, leading to death.
REPORT-HF reflects real-world practice and shows 
variations in practice that might be determined by locally 
available resources, skills, and guidelines. Values for 
plasma natriuretic peptides were not available for almost 
10 000 patients and were therefore not included in 
multivariable models for this analysis. For practical 
reasons, we did not take a random sample of countries or 
of clinical sites within a country. The registry required 
patients to give consent for the use of their data and for 
follow-up. Patients who could not provide consent could 
not participate, which explains our low index-hospital-
isation mortality. Compassionate investigators might 
have thought it inappropriate to enrol sicker, frailer 
patients who would have difficulty in returning for 
follow-up visits. Selection bias is likely to have led to 
enrolment of younger patients with fewer comorbidities 
and a better prognosis. Despite the factors that might 
have excluded sicker patients, the 1-year mortality was 
still 20%. In North America, many of the sites chosen 
served predominantly African-American patients, who 
might develop heart failure at a younger age and have a 
worse prognosis than Americans of European descent. 
No time to event data were available for hospitalisations. 
Causes of death were determined according to the 
investigator’s opinion and were not independently 
adjudicated. This might account for why so many 
deaths were reported as unknown. Patients who die at 
home, without much additional information, are often 
adjudicated as sudden deaths in clinical trials.
The REPORT-HF international prospective registry 
shows that mortality in the year after a hospitalisation for 
acute heart failure is substantial and worse in countries 
with lower average income or greater income inequality. 
Regional variations in mortality for patients with HFrEF 
suggests that risk is modifiable and might be improved 
by greater access to expert care and medicines. In 
contrast, there appears to be little or no regional variation 
in outcome for HFpEF, which might reflect the lack of 
treatments that substantially alter outcome.
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